Myriad Genetics announced the advancement of its Precise MRD product toward a March 2026 launch, supported by new breast and colorectal cancer study data demonstrating ultrasensitive ctDNA detection. The company also released select preliminary fourth quarter and full year 2025 financial results and provided full year 2026 financial guidance.

The global single nucleotide polymorphism (SNP) genotyping market is valued at USD 8.08 billion in 2026 and is expected to reach USD 19.48 billion by 2034, growing at an 11.7% CAGR. North America leads the market while Asia Pacific shows the fastest growth. PCR-based genotyping dominates by technology, pharmacogenomics leads by application, and pharmaceutical companies are the primary end users. Key drivers include personalized medicine adoption, technological advancements, and increased genomics research investments.

The global esoteric testing market is projected to grow from $27.52 billion in 2025 to $41.56 billion by 2031 at a 7.11% CAGR, driven by rising chronic disease rates, personalized medicine demand, and liquid biopsy adoption. However, stringent regulatory frameworks and reimbursement pressures pose significant challenges to market expansion.

The pan-genomic and multi-gene panel testing market is projected to grow from US$ 8.9 billion in 2024 to US$ 25.9 billion by 2032, driven by a 12.04% CAGR. Growth is fueled by rising clinical adoption of genomics-driven diagnostics, FDA approvals of comprehensive genomic profiling tests, advances in NGS technology and bioinformatics, and expanding implementation across oncology, rare diseases, and preventive medicine. North America leads the market while Asia-Pacific shows the fastest growth.

The global reproductive genetics market is projected to grow from USD 7.31 billion in 2025 to USD 16.67 billion by 2032, with a CAGR of 12.5%. Growth is driven by rising demand for genetic testing, preimplantation genetic testing (PGT), and non-invasive prenatal testing (NIPT), though ethical and legal challenges continue to limit expansion. North America leads with 40.5% market share, while Asia Pacific is the fastest-growing region.

4D Path developed a computational platform that can predict chemotherapy response in early-stage triple-negative breast cancer using routine biopsy images, demonstrating potential for personalized cancer treatment prediction.

Myriad Genetics added F8 and FXN genes to its Foresight® Carrier Screen Universal Plus Panel, enhancing genetic screening capabilities for hemophilia A and Friedreich's ataxia, while maintaining compliance with ACMG recommendations.

Myriad Genetics published a study in The Lancet Oncology demonstrating the effectiveness of their Precise® MRD test in detecting circulating tumor DNA levels in patients with oligometastatic clear-cell renal cell carcinoma, potentially enabling treatment de-escalation.

The genetic material market is expected to experience substantial growth driven by advancements in gene therapies, personalized medicine, and biopharmaceutical research. North America leads the market in 2024, with Asia Pacific projected to be the fastest-growing region from 2025-2034.

The global liquid biopsy market is projected to grow from $4.03 billion in 2025 to $7.05 billion by 2030, driven by rising cancer incidence, precision medicine advancements, and technological innovations in early disease detection.

A survey reveals that while 80% of women are afraid of health screenings, 75% would find genetic testing reassuring. Over 50% of high-risk women would feel empowered by advanced cancer screening methods, though only 14% have undergone genetic testing.

Myriad Genetics, Inc. (MYGN) is facing a securities fraud investigation after its Q1 2025 financial results showed a decline in revenue and reduced guidance for the year, causing a significant drop in its stock price.